Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis. / Zhang, D. G.; Yao, Y.; Ali, Z.; Thomsen, S.

I: Drugs of the Future, Bind 46, Nr. 6, 2021, s. 431-441.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Zhang, DG, Yao, Y, Ali, Z & Thomsen, S 2021, 'Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis', Drugs of the Future, bind 46, nr. 6, s. 431-441. https://doi.org/10.1358/dof.2021.46.6.3293576

APA

Zhang, D. G., Yao, Y., Ali, Z., & Thomsen, S. (2021). Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis. Drugs of the Future, 46(6), 431-441. https://doi.org/10.1358/dof.2021.46.6.3293576

Vancouver

Zhang DG, Yao Y, Ali Z, Thomsen S. Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis. Drugs of the Future. 2021;46(6):431-441. https://doi.org/10.1358/dof.2021.46.6.3293576

Author

Zhang, D. G. ; Yao, Y. ; Ali, Z. ; Thomsen, S. / Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis. I: Drugs of the Future. 2021 ; Bind 46, Nr. 6. s. 431-441.

Bibtex

@article{599356fb1b6e42139784d9de9069bf3c,
title = "Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis",
abstract = "Atopic dermatitis (AD) is one of the most common chronic skin diseases and has an unmet need for effective therapeutic options. Key components in the pathophysiology of AD rely on the JAK-STAT signaling pathway and JAK inhibition has therefore emerged as a promising novel therapeutic strategy. Abrocitinib (PF-04965842) is a JAK1-selective small molecule inhibitor, currently under investigation for the treatment of moderate to severe AD. Phase II and III clinical trials demonstrated a rapid and significant effect of abrocitinib 100 and 200 mg compared to placebo throughout all studies. Abrocitinib was well tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events. The presented results make abrocitinib a promising addition to the existing therapies for AD.",
keywords = "Atopic dermatitis, Abrocitinib, PF-04965842, Small molecule inhibitors, JAK-STAT pathway, Clinical trial, ATOPIC-DERMATITIS, TH2 CYTOKINES, EXPRESSION, DUPILUMAB, PLACEBO, PATHWAY, DISEASE",
author = "Zhang, {D. G.} and Y. Yao and Z. Ali and S. Thomsen",
year = "2021",
doi = "10.1358/dof.2021.46.6.3293576",
language = "English",
volume = "46",
pages = "431--441",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "6",

}

RIS

TY - JOUR

T1 - Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis

AU - Zhang, D. G.

AU - Yao, Y.

AU - Ali, Z.

AU - Thomsen, S.

PY - 2021

Y1 - 2021

N2 - Atopic dermatitis (AD) is one of the most common chronic skin diseases and has an unmet need for effective therapeutic options. Key components in the pathophysiology of AD rely on the JAK-STAT signaling pathway and JAK inhibition has therefore emerged as a promising novel therapeutic strategy. Abrocitinib (PF-04965842) is a JAK1-selective small molecule inhibitor, currently under investigation for the treatment of moderate to severe AD. Phase II and III clinical trials demonstrated a rapid and significant effect of abrocitinib 100 and 200 mg compared to placebo throughout all studies. Abrocitinib was well tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events. The presented results make abrocitinib a promising addition to the existing therapies for AD.

AB - Atopic dermatitis (AD) is one of the most common chronic skin diseases and has an unmet need for effective therapeutic options. Key components in the pathophysiology of AD rely on the JAK-STAT signaling pathway and JAK inhibition has therefore emerged as a promising novel therapeutic strategy. Abrocitinib (PF-04965842) is a JAK1-selective small molecule inhibitor, currently under investigation for the treatment of moderate to severe AD. Phase II and III clinical trials demonstrated a rapid and significant effect of abrocitinib 100 and 200 mg compared to placebo throughout all studies. Abrocitinib was well tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events. The presented results make abrocitinib a promising addition to the existing therapies for AD.

KW - Atopic dermatitis

KW - Abrocitinib

KW - PF-04965842

KW - Small molecule inhibitors

KW - JAK-STAT pathway

KW - Clinical trial

KW - ATOPIC-DERMATITIS

KW - TH2 CYTOKINES

KW - EXPRESSION

KW - DUPILUMAB

KW - PLACEBO

KW - PATHWAY

KW - DISEASE

U2 - 10.1358/dof.2021.46.6.3293576

DO - 10.1358/dof.2021.46.6.3293576

M3 - Journal article

VL - 46

SP - 431

EP - 441

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 6

ER -

ID: 273757762